Cysteine‐rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl‐2 pathway

Although the targeted tyrosine kinase inhibitor imatinib mesylate (IM) has achieved significant responses against CML in the clinical setting, a small proportion of patients fail to respond to IM treatment and their disease continues to progress, indicating resistance to IM therapy. As a secreted ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yanfang, Lin, Qing, Cai, Zhaolian, Hao, Taisen, Zhang, Yaohan, Zhu, Xianjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676106/
https://www.ncbi.nlm.nih.gov/pubmed/31145521
http://dx.doi.org/10.1111/cas.14083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676106/
https://www.ncbi.nlm.nih.gov/pubmed/31145521
http://dx.doi.org/10.1111/cas.14083

Ejemplares similares